AI Article Synopsis

  • - Oxaliplatin is a chemotherapy drug used to treat gastrointestinal cancers, but it can cause chemotherapy-induced peripheral neuropathy (CIPN), limiting treatment effectiveness.
  • - A pilot study is being conducted with 56 patients to investigate if acupuncture and acupressure can reduce CIPN and other chemotherapy-related side effects during treatment with 5-fluorouracil (5-FU) and oxaliplatin.
  • - Participants are randomly assigned to receive either acupuncture with self-acupressure or standard treatment, and various symptoms and side effects will be assessed over three months to evaluate the effectiveness and feasibility of this approach.

Article Abstract

Background: Oxaliplatin is a key chemotherapeutic agent in the treatment of local and metastatic gastrointestinal (GI) malignancies. Dose density and treatment adherence can be limited by chemotherapy-induced peripheral neuropathy (CIPN). Early research suggests CIPN incidence and severity may be mitigated by acupuncture, but rigorous data in GI oncology patients is limited. Here, we describe the protocol of a randomized, waitlist-controlled pilot study testing the use of preemptive of acupuncture plus acupressure to decrease CIPN and chemotherapy-related toxicities.

Methods: Patients with a GI malignancy (n = 56) with planned 5-fluorouracil (5-FU) and oxaliplatin IV (FOLFOX, FOLFIRINOX) every 2 weeks are being recruited. Additional concurrent anti-neoplastic agents may be used. Enrolled patients are randomized 1:1 to a 3-month intervention of Arm A: acupuncture with acupressure and standard-of-care treatment, or Arm B: standard-of-care alone. In Arm A, on days 1 and 3 of each chemotherapy cycle a standardized acupuncture protocol is administered and patients are taught self-acupressure to perform daily between chemotherapy treatments. Patients in both arms are given standard-of-care oral and peripheral (hands/feet) ice chip cryotherapy during oxaliplatin administration. CIPN and other symptoms are assessed at baseline, 6 weeks, and 3 months from registration. The primary endpoint is CIPN severity at 3 months (EORTC-CIPN 20). Additional endpoints evaluate CIPN incidence (CTCAE, Neuropen, tuning fork); incidence of pain, fatigue, nausea, oral dysesthesia, and anxiety; and feasibility (recruitment, retention, adherence, acceptability). If warranted, trial results will inform the design of a multi-center trial to expand testing of the intervention to a larger patient cohort.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527487PMC
http://dx.doi.org/10.1016/j.cct.2023.107273DOI Listing

Publication Analysis

Top Keywords

acupuncture acupressure
12
gastrointestinal malignancies
8
protocol randomized
8
cipn incidence
8
patients
6
cipn
6
acupuncture
5
acupressure addition
4
standard-of-care
4
addition standard-of-care
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!